Immunocore announces Fidelity’s Participation in $320M Financing
(Oxford, UK, 29 July 2015) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the participation of Fidelity Management & Research Company (“Fidelity”) in its US $320 million (£205 million) private financing round, previously announced on 16 July 2015.
Fidelity has participated in the $320 million investment syndicate that includes Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, other unnamed investors and existing shareholders.
Dr. Eliot Forster, Chief Executive Officer of Immunocore, commented on the financing round: “We are delighted to have included such well-respected, international life science investors in our fundraising. We believe the strong appetite for this financing from highly experienced global investors further underlines the value of our unique ImmTAC immuno-oncology technology and support for our broader strategy to build Immunocore into a world-leading, premier biotechnology company.”
Credit Suisse advised Immunocore on the financing round.
Cooley LLP served as legal counsel to Immunocore.
Please click on the link below to download the full Press Release: